HomeCompareOCSL vs HOLX

OCSL vs HOLX: Dividend Comparison 2026

OCSL yields 14.45% · HOLX yields 2.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCSL wins by $70.85M in total portfolio value
10 years
OCSL
OCSL
● Live price
14.45%
Share price
$11.21
Annual div
$1.62
5Y div CAGR
52.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$70.87M
Annual income
$58,988,602.24
Full OCSL calculator →
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →

Portfolio growth — OCSL vs HOLX

📍 OCSL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCSLHOLX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCSL + HOLX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCSL pays
HOLX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCSL
Annual income on $10K today (after 15% tax)
$1,228.37/yr
After 10yr DRIP, annual income (after tax)
$50,140,311.90/yr
HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
At 15% tax rate, OCSL beats the other by $50,140,044.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCSL + HOLX for your $10,000?

OCSL: 50%HOLX: 50%
100% HOLX50/50100% OCSL
Portfolio after 10yr
$35.45M
Annual income
$29,494,458.13/yr
Blended yield
83.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HOLX right now

OCSL
Analyst Ratings
5
Buy
7
Hold
Consensus: Hold
Price Target
$12.00
+7.0% upside vs current
Range: $12.00 — $12.00
Altman Z
0.1
Piotroski
6/9
HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCSL buys
0
HOLX buys
0
No recent congressional trades found for OCSL or HOLX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCSLHOLX
Forward yield14.45%2.65%
Annual dividend / share$1.62$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.4%0%
Portfolio after 10y$70.87M$23.6K
Annual income after 10y$58,988,602.24$314.03
Total dividends collected$69.85M$2.9K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldHold
Analyst price target$12.00$77.80

Year-by-year: OCSL vs HOLX ($10,000, DRIP)

YearOCSL PortfolioOCSL Income/yrHOLX PortfolioHOLX Income/yrGap
1← crossover$12,902$2,202.39$10,965$264.73+$1.9KOCSL
2$17,853$4,047.30$12,004$271.27+$5.8KOCSL
3$27,079$7,976.36$13,121$277.55+$14.0KOCSL
4$46,206$17,231.74$14,323$283.54+$31.9KOCSL
5$91,320$41,879.29$15,615$289.27+$75.7KOCSL
6$215,599$117,886.96$17,003$294.73+$198.6KOCSL
7$627,105$396,413.81$18,493$299.93+$608.6KOCSL
8$2,313,266$1,642,263.98$20,093$304.87+$2.29MOCSL
9$11,103,580$8,628,385.18$21,809$309.57+$11.08MOCSL
10$70,869,433$58,988,602.24$23,649$314.03+$70.85MOCSL

OCSL vs HOLX: Complete Analysis 2026

OCSLBDC

Oaktree Specialty Lending Corporation is a business development company specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity and management buyouts in small and mid-sized companies. It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering, and media and advertising sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies with enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies.

Full OCSL Calculator →

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →
📬

Get this OCSL vs HOLX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCSL vs SCHDOCSL vs JEPIOCSL vs OOCSL vs KOOCSL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.